Jointly Funded Research Explores Cutting-Edge RNA Sequencing in Rare Ovarian Cancer
Jointly Funded Research Explores Cutting-Edge RNA Sequencing in Rare Ovarian Cancer
STAAR Low-Grade Serous Ovarian Cancer Foundation and Not These Ovaries Fund Breakthrough Research at MD Anderson Cancer Center to Advance Low-Grade Ovarian Cancer Treatment
HOUSTON, TEXAS / ACCESS Newswire / April 30, 2025 / Two patient-driven ovarian cancer nonprofits - STAAR Low-Grade Serous Ovarian Cancer Foundation and Not These Ovaries - have awarded a $115,580 research grant to Dr. Kwong-Kwok Wong at The University of Texas MD Anderson Cancer Center to investigate new biomarkers that could improve treatment options for patients with low-grade serous ovarian cancer (LGSOC).
MD Anderson Cancer Center in Houston, TX is where the ovarian cancer research project with Not These Ovaries is being funded.
The research study will utilize long-read RNA sequencing, a cutting-edge technology that allows scientists to examine full-length RNA transcripts in greater detail than previously possible. This technique could identify novel gene fusions and biomarkers that indicate whether a patient will respond to chemotherapy or endocrine therapy - an urgent need in LGSOC, where traditional treatments often show limited effectiveness.
"This pilot project is exploring a promising technology to perform more accurate measurements of transcript activities and discover new genetic markers in low-grade serous ovarian cancer," said Dr. Wong, principal investigator at MD Anderson. "As the accuracy of long-read sequencing improves, we are optimistic about the potential in clinical applications for patients who need better options."
Currently, only 20% of LGSOC patients respond to platinum-based chemotherapy, the standard of care for other ovarian cancer types. Patients typically undergo surgery followed by chemotherapy and treatment with aromatase inhibitors, which block estrogen production. However, outcomes remain limited due to the unique biology of LGSOC and the lack of personalized therapies.
The study will analyze RNA samples from patients who have and have not responded to chemotherapy or hormone therapy, with the goal of uncovering molecular patterns that could guide treatment decisions and lead to more tailored, effective care.
"This research directly addresses the gap in options for patients with this rare and underfunded cancer," said Emily Campbell, Executive Director of Not These Ovaries. "We are proud to invest in innovative science that puts patients at the center of progress."
"STAAR was founded by LGSOC survivors to drive critical research for a disease that has been overlooked for too long," said Nicole Andrews, Chair of STAAR. "We're excited to partner with Not These Ovaries and MD Anderson to accelerate discoveries that could change lives."
About Not These Ovaries
Not These Ovaries is dedicated to quickly funding research and trials to eradicate ovarian cancer, with a focus on understudied and underfunded subtypes that primarily affect younger women. Its transparent model ensures 100% of donations fund immediate research and trials, while also empowering patients and families through education and actionable information.
https://www.nottheseovaries.org/
About STAAR Low-Grade Serous Ovarian Cancer Foundation
STAAR raises critical funds for life-saving research focused on low-grade serous ovarian cancer (LGSOC), a rare and often misunderstood subtype affecting fewer than 10% of ovarian cancer patients. Founded by LGSOC patients, STAAR drives innovation in diagnostics and treatments while collaborating with global research partners to advance care for this community.
https://www.staaroc.org/
Contact Information
Emily Campbell
Executive Director
[email protected]
(786) 814-1700
SOURCE: Not These Ovaries
View the original press release on ACCESS Newswire
F.Maes--RTC
